Harmony Biosciences Third Quarter 2026 Financial Results - HARMONY BIOSCIENCES HOLDINGS INC

Explicit Guidance:

• Reiterated full-year 2026 net revenue guidance for the WAKIX franchise of $1.0 billion to $1.04 billion.
• Anticipated 2028 to 2032 revenue growth from business development assets to support a self-funded model.

Business-Segment Outlook:

• WAKIX: On track for sustained growth in year seven, with 400+ net patient additions observed in five of the last six quarters; expects growth momentum to continue through 2027 despite the upcoming launch of a competitor.
• WAKIX Life Cycle:
  • WAKIX-GR: On track for launch in the first half of 2027, with FDA PDUFA date of April 1, 2027.
  • WAKIX-HD: Phase III trials (OnStreet1 for narcolepsy, OnStreet2 for idiopathic hypersomnia) ongoing; top-line data expected in 2027 with PDUFA in 2028.
  • WAKIX-Amorphous: Exploring broader CNS indications (fatigue, neuropsychiatric) beyond the current rare disorder focus, targeting protection into the 2040s via licensing agreements.
• WAKIX Pediatric: Completing the Phase III TEMPO study in Prader-Willi syndrome (top-line data expected mid-2027) to fulfill FDA requirements for an additional six months of pediatric exclusivity, pushing exclusivity to March 2030.
• Epilepsy Franchise: EPX100 Phase III trials (Lighthouse for Lennox-Gastaut, ORCA for Dravet) actively enrolling; top-line data expected mid-2027 with PDUFA in 2028.
• WAKIX Competition: Anticipates Takeda's Orzapil (Orexin antagonist) launch within the current quarter; notes Orzapil is indicated only for NT1, whereas WAKIX retains broad utility across NT1, NT2, and pediatrics.

Market and Competitive Outlook:

• BP205 (Orexin-2 Agonist): Preliminary Phase 1 MAD data supports a "best-in-class" profile; initiated Phase 1b sleep-deprived healthy volunteer study with top-line efficacy data expected Q1 2027.
• Phase 2 Strategy: Multiple Phase 2 studies across CNS indications (Sleep, Epilepsy, broader CNS) planned to initiate mid-2027.
• Combination Therapy: Investigating synergistic potential of combining BP205 with histaminergic agents (like WAKIX) for narcolepsy, leveraging distinct mechanisms of action.
• Competitive Landscape: Maintains confidence in WAKIX exclusivity to March 2030 via a multi-layered IP strategy covering polymorph, method of use, and amorphous form patents.

Macro / Industry Outlook:

• Patent Litigation:
  • ANDA Litigation (AET Pharma): Bench trial concluded; expects ruling on polymorph and method of use patents around February 2027 (30-month stay expiration).
  • Preliminary Injunction (PI): Hearing scheduled for January 26, 2027, with decision expected by February 14, 2027.
  • Amorphous Patent Litigation (Novidium/AET/Sandoz): Trial expected to be scheduled in 2029; aims to protect franchise through the 2040s.
• Market Dynamics: Operating in a highly polypharmacy market; notes strong payer coverage (>80% of lives) and high HCP awareness for WAKIX.

Strategic Initiatives:

• Leadership Transition: Dr. Jeffrey Dano stepping down as CEO on December 31, 2026; Peter Anastasiou (current COO) becoming President and CEO effective January 1, 2027. Dano will remain as advisor throughout 2027.
• Business Development (BD):
  • Leveraging >$1 billion cash balance to pursue two categories: (1) assets adding near-term revenue (Phase 3/On Market) for 2028–2032; (2) innovative pipeline assets for long-term value.
  • Seeking M&A and licensing deals across sleep, epilepsy, rare orphan CNS, and broader CNS indications (including mood, cognition, attention).
• R&D Investment: Continued funding of BP205 development and Phase III registrational studies.

Risks and Headwinds to Outlook:

• Litigation: Uncertainty remains regarding the final outcome of ANDA and amorphous patent litigation, though the company maintains strong confidence in prevailing on at least one patent to maintain exclusivity to 2030.
• Clinical Execution: Potential for unexpected safety signals or efficacy gaps in the upcoming sleep-deprived volunteer study or Phase 2 trials for BP205.
• Competitive Launch: Impact of Takeda's Orzapil launch, though management views this as niche (NT1 only) and not a significant threat to WAKIX's broad franchise.
• Cost Pressures: Increased Cost of Goods Sold (30% of revenue) due to new royalty agreements with Novidium and milestone payments.

Management Tone on the Future:

• Confidence: High confidence in WAKIX's growth trajectory and the "best-in-class" potential of BP205.
• Continuity: Emphasizes "continuity, strength, and growth" regarding the CEO transition; no anticipated change to strategic priorities.
• Capital Discipline: Expresses confidence in maintaining a strong balance sheet while funding R&D and multiple BD transactions.

Miscellaneous:

• Financials: Q3 2026 net revenue was $269 million; net income was $48 million ($0.81/share).
• Pipeline Catalysts: Multiple data readouts expected in 2027 for BP205, WAKIX-HD/GR, WAKIX (Prader-Willi), and EPX100, with target PDUFA dates in 2028.
• Safety Profile: BP205 showed mild target engagement AEs (insomnia <20%, urinary frequency/urgency <20% at higher doses) with no discontinuations in Phase 1; headache (25%) was non-discontinuing.